Dihashita Tablets 50/1000 mg
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
(Co., Ltd.) AProgen Biologics
MFDS item code 201506652 · Approved 2015.09.21
This product's status changed to Approval withdrawn on 2023.08.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used in conjunction with dietary and exercise therapies to help control blood sugar in patients with type 2 diabetes. If blood sugar control is difficult and there is no previous experience with diabetes medication, it may be used alone. It can also be used as an alternative when monotherapy with metformin or sitagliptin is insufficient, or in combination with both drugs. This drug will be added to combination therapy when blood sugar control is difficult with metformin combined with sulfonylureas or thiazolidinediones. It is also used in combination with insulin and metformin if blood sugar control is insufficient. Therefore, this drug is used to improve blood sugar control in various cases of patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is one tablet of this medicine 50/500 mg twice daily. The dose may be increased to one tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).
This drug contains sitagliptin and metformin, antidiabetic agents that help control blood sugar. While taking this drug, serious allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, stop taking the drug immediately and consult a physician. There is a risk of pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, notify healthcare professionals immediately. This drug should not be administered to patients with severely impaired kidney function or patients with acute diseases such as severe infections, dehydration, or acute myocardial infarction. Before undergoing tests using radiocontrast iodine agents, this drug should be temporarily discontinued, and it should be resumed only after confirming that kidney function is normal post-examination. It is safe for pregnant or breastfeeding women not to take this drug. This drug may cause hypoglycemia, so when taken with other hypoglycemic agents, blood sugar levels should be checked frequently, and attention should be paid to symptoms of hypoglycemia. Maintain regular meals and adequate exercise while taking this medication, and have regular kidney function and blood tests. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking alcohol while on this medication. If oral intake is difficult due to surgery or serious illness, this drug should be temporarily discontinued, and it can be restarted once the condition improves. Gastrointestinal side effects such as diarrhea, nausea, or headache may occur during the use of this drug, and if symptoms are severe, consult healthcare professionals. Elderly patients are at risk of reduced kidney function, so they should have frequent kidney function tests before and during treatment, and dosage adjustments may be necessary. In case of an overdose of this drug, immediately visit a healthcare facility for appropriate treatment, as some components can be removed by dialysis. There may be drug interactions, so if there are other medications being taken, it is essential to inform the healthcare provider, especially when combined with drugs affecting kidney function. If there are unusual symptoms or discomfort while taking this drug, it is important to consult healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
Store this drug in a tightly closed container to prevent air or moisture from entering, and it is advisable to keep it at room temperature between 1 degree and 30 degrees Celsius.
Dark red oval film-coated tablets
28 tablets/PTP, 56 tablets/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
(Co., Ltd.) AProgen Biologics
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.